جست‌وجوی استاد و پژوهشگر

Harris H. Wangمشاهده پروفایل

دانشیار

• Systems Biology
• Synthetic Biology
• Genome Engineering
• +۱۷ مورد دیگر

Harris H. Wang is an Associate Professor in the Department of Systems Biology and Department of Pathology and Cell Biology at Columbia University's Vagelos College of Physicians and Surgeons, where he also serves as Interim Chair of Systems Biology. He is affiliated with the Center for Computational Biology and Bioinformatics (C2B2) and the Integrated Program in Cellular, Molecular and Biomedical Studies (CMBS). B.S., Physics and Mathematics, MIT Ph.D., Biophysics, Harvard University Dr. Wang's research lies at the intersection of systems and synthetic biology, focusing on developing foundational technologies for genome engineering, microbiome manipulation, and synthetic genomics. His lab pioneers methods such as MAGE, MAGIC, CAST, and CAMII to enable high-throughput genetic manipulation, in situ microbiome engineering, and AI-driven microbial culturomics. Key research themes include understanding microbial community dynamics, engineering cellular memory systems, designing biocontained genetic circuits, and applying synthetic biology to human health challenges in personalized medicine and infectious disease. His recent publications reveal a strong trend in spatial and functional metagenomics, CRISPR-based microbiome editing, and synthetic biology tools for data storage and genetic stability. The articles span high-impact journals like Nature , Science , and Nature Biotechnology , reflecting his leadership in developing scalable, programmable biological systems. Scientific Awards: NIH Director’s Early Independence Award Forbes 30 Under 30 in Science Sloan Research Fellowship NSF CAREER Award ONR Young Investigator Award Burroughs Wellcome Fund PATH Award Schaefer Scholar Blavatnik National Award Vilcek Prize PECASE Dr. Wang has advised numerous PhD and postdoctoral researchers, many of whom have gone on to independent scientific careers. His lab is supported by major grants from NIH, NSF, DARPA, DOE, and foundations including the Bill & Melinda Gates Foundation and CZ Biohub NY. He is actively involved in educational initiatives, including organizing Columbia’s iGEM team and the Cold Spring Harbor Laboratory Synthetic Biology course. The Wang Lab is based at the Columbia University Irving Medical Center and is part of national consortia such as the Engineering Biology Research Consortium (EBRC) and the Genome Project-Write (GP-Write) initiative. The lab develops and applies cutting-edge technologies in automation, machine learning, and synthetic biology to engineer microbiomes for applications in medicine, global health, and climate change.

Vikramaditya G. Yadavمشاهده پروفایل

دانشیار

• Biocatalysis
• Bioremediation
• Bioprocess engineering
• +۱۵ مورد دیگر

Vikramaditya G. Yadav is an Associate Professor at the University of British Columbia (UBC) in the Department of Chemical and Biological Engineering, Faculty of Applied Science. He directs the Master of Engineering Leadership (MEL) Program in Sustainable Process Engineering and leads the BioFoundry research group. Education: B.A.Sc., University of Waterloo (2007) Ph.D., Massachusetts Institute of Technology (2013) Postdoctoral Associate, Harvard University (2014) His research spans sustainable chemical manufacturing, metabolic engineering, and biotechnology. Key areas include: Designing biosynthetic enzymes for biomass valorization Developing bioremediation strategies for industrial water quality Creating innovative drug delivery systems and tissue engineering solutions Advancing synthetic biology for pharmaceutical and bioenergy applications His recent work focuses on ocular drug delivery, cannabinoid biosynthesis in E. coli, lignin-based nanoparticles for cancer therapy, and computational analysis of plant secondary metabolites. Collaborations with start-ups, industry, and medical labs drive innovation in Canada's bioeconomy. Professional Leadership: Chair, Biotechnology Division of the Chemical Institute of Canada Associate Editor, The Canadian Journal of Chemical Engineering He is affiliated with UBC's BioProducts Institute and contributes to project-based learning pedagogy.

Kristian Helinمشاهده پروفایل

استاد

• Cancer biology
• Epigenetics
• Stem cells
• +۵ مورد دیگر

Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.

Vakil Takhaveevمشاهده پروفایل

مدرس

• DNA Damage and Repair
• Aging Mechanisms
• Cancer Biology
• +۶ مورد دیگر

Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.

Paul Stuppleمشاهده پروفایل

استاد

• Small Molecule Drug Discovery
• Cancer Therapeutics
• Pharmaceutical Chemistry
• +۳ مورد دیگر

Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.

Weiping Tangمشاهده پروفایل

استاد

• Targeted Protein Degradation
• PROTACs
• Medicinal Chemistry
• +۵ مورد دیگر

Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.

Michele Klingbeilمشاهده پروفایل

استاد

• Parasitology
• Molecular Biology
• Microbiology
• +۴ مورد دیگر

Michele Klingbeil is a Professor in the Department of Microbiology at the University of Massachusetts Amherst, where she leads the Klingbeil DNA Replication Laboratory. She received her PhD in Cell and Molecular Biology from the University of Toledo in 1996 and previously worked at Johns Hopkins School of Medicine before moving to UMass in July 2007. Her educational background includes: PhD in Cell and Molecular Biology, University of Toledo, 1996 Dr. Klingbeil's research focuses on the unique biology of trypanosomatid parasites, particularly Trypanosoma brucei , the causative agent of African sleeping sickness. Her laboratory investigates two main areas: (1) replication of the unusual mitochondrial DNA network called kinetoplast DNA (kDNA), and (2) nuclear DNA replication initiation. Her work on kDNA is particularly significant as this structure is essential for parasite survival but has no counterpart in mammalian hosts, making it an attractive drug target. She employs a combination of reverse genetics (RNAi), cell biology, and biochemistry to understand the replication and repair mechanisms of kDNA, with a special focus on a family of four DNA polymerases related to bacterial Pol I. Dr. Klingbeil's recent publications reveal her laboratory's deep investigation into mitochondrial DNA polymerases in trypanosomatids, with discoveries showing multiple polymerases having specialized functions in kDNA replication and repair. Her research has established that several of these polymerases are essential for parasite viability, opening new avenues for drug development. She has also made significant contributions to understanding the simplified Origin Recognition Complex in trypanosomatids compared to other eukaryotes. Dr. Klingbeil has received the Thomas G. Lessie Distinguished Lectureship Award for her impact on teaching at the graduate level. Her research is funded by the National Institutes of Health, U.S. Department of Agriculture, the Joeph P. Healey Endowment, and the University of Massachusetts Amherst. She has mentored numerous graduate and undergraduate students, including current PhD candidates Dave Bruhn, Jeniffer Concepción, and Juemin Luo, as well as visiting scholar Eva Vidal Rico. Her former students have gone on to positions at institutions including Dana Farber/Broad Institute, Regis College, and Flagship Ventures. The laboratory regularly participates in scientific conferences including the Molecular Parasitology Meeting at Woods Hole and the Kinetoplastid Molecular Cell Biology conference. Dr. Klingbeil teaches several courses including Parasitology (MICRO 590S), Parasitology Lab (MICRO 590L), Molecular Mechanisms of Pathogenesis (MICRO 797P), Advanced Cell Biology (MCB 641), and Writing in Microbiology (MICRO 360). Her laboratory organizes regular social events including pumpkin carving parties and outings to Six Flags New England and Mt. Sugarloaf.

David Vocadloمشاهده پروفایل

استاد

• Bioorganic Chemistry
• Chemical Biology
• Glycobiology
• +۳ مورد دیگر

David Vocadlo is a Distinguished Professor of Chemistry and Molecular Biology & Biochemistry at Simon Fraser University (SFU), holding the Canada Research Chair in Chemical Biology. His research focuses on Chemical Glycobiology, investigating carbohydrate-processing enzymes and developing chemical tools to study glycan roles in health and disease. His lab explores O-GlcNAc signaling, neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), and enzyme inhibitors for therapeutic applications. Education: PhD from University of British Columbia (UBC), followed by a CIHR postdoctoral fellowship at UC Berkeley. Key roles include E.W.R. Steacie Memorial Fellow and Royal Society Fellow. Research highlights include O-GlcNAcase inhibitors for neuroprotection, glycan structure-function relationships, and enzyme activity imaging tools. Collaborates globally with experts in glycobiology and employs cutting-edge techniques like chemical synthesis, mass spectrometry, and live-cell imaging. Awards: Distinguished Professor title, Canada Research Chair, Royal Society Fellowship. Active in training researchers through SFU’s graduate programs, emphasizing interdisciplinary approaches. Lab members work on topics ranging from enzyme mechanisms to disease modeling.

Zhe Jiمشاهده پروفایل

استادیار

• Data Science
• Computational Biology
• Functional Genomics
• +۴ مورد دیگر

Zhe Ji is an Assistant Professor in the Department of Biomedical Engineering at McCormick School of Engineering and the Department of Pharmacology at Feinberg School of Medicine, Northwestern University. His research integrates computational and experimental genomics to study gene transcription and RNA translation in cell fate commitment and oncogenic processes, aiming to develop precision medicine strategies. **Education**: Postdoctoral Fellow in Cancer Systems Biology, Harvard Medical School Postdoctoral Fellow in Computational Biology, Broad Institute of MIT and Harvard Ph.D. in Computational Genomics, Rutgers University B.S. in Biotechnology, Nanjing University, China **Research Focus**: Keywords include Data Science, Computational Biology, Functional Genomics, RNA, Cancer, Inflammation, and Machine Learning. The lab explores regulatory mechanisms underlying disease, with a focus on translational control, cancer metastasis, and inflammatory networks. **Grants & Advising**: No specific grants or student advisees listed. The lab emphasizes collaborative projects and computational-experimental approaches. **Lab Affiliations**: Zhe Ji’s lab is part of Northwestern’s interdisciplinary environment, bridging engineering and medicine to advance genomic technologies and therapeutic strategies.

Guoyao Wuمشاهده پروفایل

استاد

• Animal Nutrition
• Protein and Amino Acid Metabolism
• Nutritional Biochemistry
• +۵ مورد دیگر

Guoyao Wu is a Distinguished Professor of Animal Nutrition at Texas A&M University's College of Agriculture & Life Sciences, holding dual appointments in the Department of Animal Science and the Graduate Faculty of Nutrition. His expertise spans nutritional biochemistry, protein metabolism, and reproductive physiology. Dr. Wu earned his B.Sc. from South China Agricultural University, M.Sc. degrees from Beijing Agricultural University and the University of Alberta, and a Ph.D. from the University of Alberta, followed by postdoctoral training at McGill University and Memorial University of Newfoundland. His research focuses on amino acid and protein metabolism across molecular, cellular, and whole-animal levels, using models like cattle, pigs, and aquatic species. Key areas include placental nutrient transport, fetal programming, and the role of amino acids in mitigating conditions like sarcopenia and intrauterine growth restriction. He has pioneered studies on glycine, creatine, and citrulline supplementation in livestock and aquaculture. Dr. Wu has received over 15 prestigious awards from China, Canada, and the U.S., including the Thousand-People-Talent Award and Changjiang Scholar Award. He serves on editorial boards of journals like Amino Acids and Frontiers in Bioscience , and teaches graduate courses in protein metabolism. His work bridges basic science and applied nutrition, with implications for improving livestock productivity, human health, and aquaculture sustainability. Current projects address amino acid requirements of companion animals, microgravity effects on metabolism, and placental biology in ruminants.

Mark Wallaceمشاهده پروفایل

استاد

• Membrane Biology
• Biophysics
• Optical Microscopy
• +۳ مورد دیگر

Mark Wallace is a Professor of Chemistry at King's College London, affiliated with the Department of Chemistry and the Faculty of Natural, Mathematical & Engineering Sciences. He holds a Royal Society University Research Fellowship (2005–2016) and has been a lecturer at Oxford University before joining King's in 2016. His research focuses on membrane protein function and artificial membrane mimics, combining optical microscopy and nanotechnology. He earned a PhD from the University of Cambridge (2002) and postdoctoral training at Stanford University and the National Institute for Medical Research. Key research interests include membrane protein dynamics, lipid bilayer engineering, and single-molecule imaging. He has pioneered techniques like droplet interface bilayers and interferometric scattering microscopy. His work has led to patents and applications in molecular sensing and medical research. Awards include the 2002 Gregorio Weber Prize and the 2015 RSC Norman Heatley Award. He is actively involved in public outreach, including video podcasts and educational competitions. Recent publications emphasize artificial ion channels, nanoparticle formation monitoring, and mitochondrial protein dynamics. His lab collaborates with institutions like the London Centre for Nanotechnology and the Rosalind Franklin Institute. Over 30 students and researchers have been mentored, with active grants from EPSRC, Wellcome Trust, and BBSRC.

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +۱۲ مورد دیگر

Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.

Sebastian Schuckمشاهده پروفایل

استاد

• Cell Biology
• Molecular Biology
• Membrane Biology
• +۴ مورد دیگر

Overview Sebastian Schuck is a Professor of Biochemistry and Molecular Cell Biology at Heidelberg University's Biochemistry Center (BZH). His research focuses on organelle homeostasis, particularly the endoplasmic reticulum (ER), with emphasis on ER membrane biogenesis, ER-phagy, and SHRED pathways. He leads an international team investigating how cells adapt ER structure and function under stress or disease conditions. Education & Career Since 2021: Professor at Heidelberg University BZH 2013–2021: Independent Group Leader at Heidelberg University's Center for Molecular Biology 2006–2013: Postdoc with Peter Walter at UCSF 2001–2006: PhD and Postdoc with Kai Simons at Dresden's Max Planck Institute 1995–2000: Biochemistry studies at Universities of Hannover and Tübingen Research Interests Dr. Schuck's lab explores molecular mechanisms underlying ER homeostasis, including: 1. ER expansion during stress via lipid synthesis 2. Microautophagy-mediated ER degradation via ESCRT machinery 3. SHRED pathway regulation of proteasomal degradation of misfolded proteins 4. Links between ER stress and neurodegenerative diseases/cancer Awards & Honors No specific awards listed, but recognized for pioneering contributions to understanding microautophagy and ER quality control mechanisms. Advising & Collaborations Advised over 20 PhD/Master's students and postdocs Collaborations with Carlos Bas-Orth (MPI Biochemistry), Liam Holt (NY), and others Labs & Teams Current lab includes 10+ members focusing on: - Human ER morphogenesis - Microautophagy dynamics - SHRED pathway mechanisms

Amit R. Reddiمشاهده پروفایل

استاد

• Biochemistry
• Metalloproteins in biological regulation and disease
• Heme trafficking and signaling
• +۴ مورد دیگر

Amit R. Reddi is a Professor at the Department of Chemistry, Georgia Institute of Technology. His research focuses on metalloproteins, particularly the mechanisms of heme trafficking and redox signaling in relation to cancer, neurodegenerative disorders, and infectious diseases. He has received numerous awards for both research and teaching excellence. Education : B.A. from Carleton College (2003) Ph.D. from Columbia University (2008) NIH Postdoctoral Fellowship at Johns Hopkins University (2013) Research Interests : The Reddi laboratory investigates cellular mechanisms of metalloprotein activation and inter-biomolecular communication in metabolic and signaling pathways critical to human health. Key projects explore heme trafficking pathways and the role of Cu/Zn Superoxide Dismutase (SOD1) in redox signaling, with implications for cancer, neurodegenerative diseases, and microbial pathogenesis. Scientific Awards : Vasser Woolley Faculty Fellowship (2021) Student Recognition of Excellence in Teaching Class of 1934 Award (2021) CTL/BP Junior Faculty Excellence in Teaching Award (2019) Bergmann Memorial Award (2018) Blanchard Professorship (2016) NSF CAREER Award (2015) NIH NRSA Post-doctoral Fellowship (2008-2011) Grants & Fellowships : NSF CAREER Award (2015) Sigma Xi Grants-In-Aid-of-Research (2003) NIH Cancer Research Training Award Fellowship (1999-2001)

Amy E. Fraleyمشاهده پروفایل

استادیار

• Natural Products Biosynthesis
• Biotechnology
• Biochemistry
• +۶ مورد دیگر

Amy E. Fraley is an Assistant Professor at ETH Zürich, Department of Chemistry and Applied Biosciences, and leads the Medicinal Chemistry Research Group. Her cross-disciplinary work bridges natural products biosynthesis, pharmaceutical sciences, and environmental sustainability through enzymatic chemistry and biotechnology. BSc in Chemistry, Millersville University of Pennsylvania (2014) PhD in Medicinal Chemistry, University of Michigan College of Pharmacy (2019) Postdoctoral work at ETH Zürich Institute of Microbiology under Prof. Jörn Piel Her research focuses on harnessing biosynthetic enzymes (e.g., halogenases, monooxygenases, Diels-Alderases) to create sustainable bioactive metabolites. She explores natural product biosynthesis in fungi and marine bacteria, targeting disease mechanisms and green chemistry applications. Recent work includes metagenomic studies of Lake Chilika microbial mats and polyketide synthase engineering. Notable scientific awards include the 2024 JSP Fellow at Bürgenstock Conference, 2018 Rackham Predoctoral Fellowship, and multiple University of Michigan honors. Her group secured funding from the ETH4D Doctoral Mentorship Grant and Messerli Foundation . Collaborations span structural biology, synthetic chemistry, and microbiology, with key contributions to flavoenzyme characterization and bioactive compound libraries . The lab emphasizes interdisciplinary training and innovation in biocatalytic tools for organic synthesis.